An inspiring fact was that all CTLA4, LAG3 and TIGIT tend to express higher in high-risk group of patients which was categorized based on the gene signature (Fig. 8F), and the distribution shall be an additional support besides above ESMINATE immune score evaluation result for indicating the immune targeting potential for this group of ccRCC patients. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.